Pegapamodutide is a synthetic peptide commercialized by OPKO Health, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Pegapamodutide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Pegapamodutide is expected to reach an annual total of $61 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Pegapamodutide Overview

Pegapamodutide (LY-2944876) is under development for the treatment of type 2 diabetes and obesity. It is administered once or twice weekly through subcutaneous route. LY-2944876 is an Oxyntomodulin peptide that acts on glucagon-like peptides-1 (GLP-1) receptor and glucagon receptor.

OPKO Health Overview

OPKO Health (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals products. The company’s product portfolio includes 4K score test used for diagnosis of prostate cancer; Rayaldee (calcifediol), an extended-release capsule for treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease; and the Claros analyzer, a blood performance test. OPKO develops products using proprietary technologies including, Carboxyl Terminal Peptide (CTP) technology, and AntagoNAT technology. It is advancing pipeline products targeted for the treatment of hypophosphatemia, obesity, diabetes, haemophilia, growth hormone deficiency, dravet syndrome and other diseases. It also offers veterinary products. The company has operational presence with offices located in Chile, Mexico, Spain, Ireland, Canada and Israel. OPKO is headquartered in Miami, Florida, the US.

The company reported revenues of (US Dollars) US$1,774.7 million for the fiscal year ended December 2021 (FY2021), an increase of 23.6% over FY2020. In FY2021, the company’s operating margin was 1.1%, compared to an operating margin of 4% in FY2020. The net loss of the company was US$30.1 million in FY2021, compared to a net profit of US$30.6 million in FY2020. The company reported revenues of US$179.7 million for the third quarter ended September 2022, a decrease of 42% over the previous quarter.

For a complete picture of Pegapamodutide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.